OverviewChartNewsTraderScreen

Esperion Therapeutics/  US29664W1053  /

IEX
2024-05-15  9:59:51 PM Chg. +0.14 Volume Bid- Ask- High Low
2.32USD +6.44% 43,803
Turnover: 97,590.57		 -Bid Size: - -Ask Size: - 2.32 2.15
GlobeNewswire 05-14 Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET...
GlobeNewswire 05-10 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 05-07 Esperion Reports First Quarter 2024 Financial Results
GlobeNewswire 05-02 Beyond, Inc. Announces Key Additions to Leadership Team
GlobeNewswire 04-29 Esperion to Participate in Upcoming May Investor Conferences
GlobeNewswire 04-23 Esperion to Report First Quarter 2024 Financial Results on May 7
GlobeNewswire 04-07 Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (...
GlobeNewswire 04-01 Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
GlobeNewswire 03-27 One Biosciences Welcomes Dr. Scott Braunstein and Dr. Vincent Miller to its Board of Directors
GlobeNewswire 03-26 Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire 03-25 Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & ...
GlobeNewswire 03-22 U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiova...
GlobeNewswire 03-22 CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose ...
GlobeNewswire 02-27 Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 02-16 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 02-13 Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
GlobeNewswire 02-01 RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
GlobeNewswire 01-23 Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ ...
GlobeNewswire 01-19 Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
GlobeNewswire 01-18 Esperion Announces Proposed Public Offering of Common Stock
GlobeNewswire 01-03 Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including...
GlobeNewswire 2023-12-18 Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2023-12-13 U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXL...
GlobeNewswire 2023-11-13 Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at Ame...
GlobeNewswire 2023-11-11 Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American...